Kisspeptin Dosage: The Rare Case With Real Human Trials

Summary: Most research peptides have no human trials. This one has a substantial academic programme, which changes what a dosage question can and cannot be answered from.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Kisspeptin turns up alongside the usual research peptides, and the assumption that travels with it is that the evidence looks the same. It does not, and the difference is worth stating plainly before anything about quantities.

There is a real research programme

ClinicalTrials.gov lists roughly 45 registered studies under the name. Four are Phase 3, nine are Phase 2, eleven are Phase 1, and about 26 are recorded as completed.

The sponsors are the more telling detail. The largest blocks belong to an individual academic investigator and to Massachusetts General Hospital, with further entries from Imperial College London and university hospitals elsewhere. This is reproductive endocrinology research, not a vendor programme, and PubMed carries several thousand records on the peptide and its receptor.

Almost nothing else covered on this site looks like that. For comparison, BPC-157 has two genuine Phase 1 records and MOTS-c has none.

What that research was actually asking

This is where the dosage question gets complicated rather than easier.

Kisspeptin is a regulator of the reproductive axis. It acts upstream of GnRH and drives the release of luteinising hormone, which is why the clinical work clusters around puberty disorders, hypogonadotropic hypogonadism, fertility, and its use as a trigger in assisted reproduction.

So there is genuine human dosing experience, and it exists inside a clinical context: a defined patient group, a measured hormonal endpoint, and supervision. The amounts used were chosen to produce a hormonal response that somebody was measuring, not to produce a general effect in a healthy person.

Why an approved label still does not exist

No regulator has approved kisspeptin as a marketed medicine. A substantial trial programme and an approved product are different achievements, and only the second produces a label with authorised quantities.

That is the gap a kisspeptin dosage chart has to sit in. It can restate quantities used in published human studies, which is a genuinely stronger source than the rodent conversions behind most peptide charts. What it cannot do is present them as an authorised dose, because no authority has set one.

The honest summary

Real human data, no approved product. Quantities that exist in the literature but are tied to clinical questions about the reproductive axis, measured by hormone assays in supervised settings.

Anyone reading a chart for this compound should check one thing above all: whether the figures are attached to the study population and the endpoint they came from. With most peptides that check fails because there is no study to attach them to. Here there is, which makes the omission less excusable rather than more.